Dennis Gillings to step down as Quintiles chairman

Eric Sagonowsky FierceBiotech News

England’s price watchdog writes off Celgene’s Imnovid in final guidance

Emily Wasserman The U.K.'s cost-effectiveness gatekeeper is singing an increasingly harsh tune when it comes to greenlighting cancer drugs, and Celgene's Imnovid is the latest ...

Activists ready to fight for Ariad CEO’s ouster: CNBC

Carly Helfand Industry-watchers knew a shake-up could be in Ariad Pharmaceuticals' future when Alex Denner, founder of activist hedge fund Sarissa Capital and protégé ...

Biotech boom drives blockbuster VC investments in Boston, San Francisco

John Carroll The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the ...

Intrexon takes a $60M flyer on a synthetic biology startup

Damian Garde Billionaire R.J. Kirk's Intrexon has signed a $ 60 million deal to acquire ActoGeniX, a Belgian biotech at work on oral drugs designed to generate therapeutic proteins ...

Eisai nabs quick FDA blessing for cancer blockbuster hopeful Lenvima

Carly Helfand Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start ...

Eisai wins an early FDA nod for its self-described cancer blockbuster

Damian Garde Eisai is counting on its new cancer drug to eventually bring in more than $ 1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head ...

Bayer’s Brandicourt said to top Sanofi CEO list: Bloomberg

Eric Palmer Sanofi Chairman Serge Weinberg recently brushed away suggestions that the French drugmaker was having a hard time finding someone who wanted to be CEO of the company. Now ...

The curious case of Xoma.com

Damian Garde On Thursday, all of the content on Xoma's website was replaced by a single phrase. FierceBiotech News

Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU

Eric Palmer Just days after Gilead COO John Milligan told investors to expect negotiations for its hep C franchise to unfold very quickly in Europe, Germany has said it has a deal to ...

Bone Therapeutics, Poxel burst out of the gate with oversubscribed IPOs

Nick Paul Taylor Bone Therapeutics and Poxel have started life on European public markets with a bang. Both companies priced within their target ranges, sold out their overallotments ...

Docs, drugmakers conspire on lucrative new doses of old meds: NYT

Tracy Staton Behind the usual pharma scenes is a network of doctors, small drugmakers and distributors hawking new dosages of old drugs, a practice that allows physicians to dispense ...
Page 5 of 9« First...34567...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS